JP2014519319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519319A5 JP2014519319A5 JP2014510472A JP2014510472A JP2014519319A5 JP 2014519319 A5 JP2014519319 A5 JP 2014519319A5 JP 2014510472 A JP2014510472 A JP 2014510472A JP 2014510472 A JP2014510472 A JP 2014510472A JP 2014519319 A5 JP2014519319 A5 JP 2014519319A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequences
- methylation
- cancer
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 168
- 230000011987 methylation Effects 0.000 claims description 136
- 238000007069 methylation reaction Methods 0.000 claims description 136
- 238000000034 method Methods 0.000 claims description 126
- 239000000523 sample Substances 0.000 claims description 69
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 54
- 239000012472 biological sample Substances 0.000 claims description 23
- 238000004458 analytical method Methods 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 19
- 238000004393 prognosis Methods 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108091029523 CpG island Proteins 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 238000003752 polymerase chain reaction Methods 0.000 claims description 8
- 238000011269 treatment regimen Methods 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 6
- 238000000513 principal component analysis Methods 0.000 claims description 6
- 238000007619 statistical method Methods 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 230000006607 hypermethylation Effects 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000003200 Adenoma Diseases 0.000 claims description 4
- 206010001233 Adenoma benign Diseases 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 238000007855 methylation-specific PCR Methods 0.000 claims description 4
- 238000002493 microarray Methods 0.000 claims description 4
- 238000012775 microarray technology Methods 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 238000012175 pyrosequencing Methods 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 230000005012 migration Effects 0.000 claims description 3
- 238000013508 migration Methods 0.000 claims description 3
- 238000009104 chemotherapy regimen Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000001134 F-test Methods 0.000 description 3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019166951A JP6954964B2 (ja) | 2011-05-12 | 2019-09-13 | エピジェネティックドメインの安定性の全般的な損失を通して癌を検出する方法およびその組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161518892P | 2011-05-12 | 2011-05-12 | |
| US61/518,892 | 2011-05-12 | ||
| PCT/US2012/037362 WO2012154979A2 (en) | 2011-05-12 | 2012-05-10 | Method of detecting cancer through generalized loss of stability of epigenetic domains, and compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019166951A Division JP6954964B2 (ja) | 2011-05-12 | 2019-09-13 | エピジェネティックドメインの安定性の全般的な損失を通して癌を検出する方法およびその組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014519319A JP2014519319A (ja) | 2014-08-14 |
| JP2014519319A5 true JP2014519319A5 (https=) | 2015-06-25 |
Family
ID=47140012
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510472A Withdrawn JP2014519319A (ja) | 2011-05-12 | 2012-05-10 | エピジェネティックドメインの安定性の全般的な損失を通して癌を検出する方法およびその組成物 |
| JP2019166951A Active JP6954964B2 (ja) | 2011-05-12 | 2019-09-13 | エピジェネティックドメインの安定性の全般的な損失を通して癌を検出する方法およびその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019166951A Active JP6954964B2 (ja) | 2011-05-12 | 2019-09-13 | エピジェネティックドメインの安定性の全般的な損失を通して癌を検出する方法およびその組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10752953B2 (https=) |
| EP (1) | EP2707506B1 (https=) |
| JP (2) | JP2014519319A (https=) |
| AU (1) | AU2012253414B2 (https=) |
| WO (1) | WO2012154979A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016349709A1 (en) * | 2015-11-06 | 2018-05-31 | University Of Southern California | Development of prognostic markers dsg-3 from the saliva of oral cancer patients |
| EP3885447B1 (en) * | 2016-05-30 | 2024-01-10 | The Chinese University Of Hong Kong | Detecting hematological disorders using cell-free dna in blood |
| EP3472358B1 (en) * | 2016-06-16 | 2021-08-18 | The Johns Hopkins University | Methods and system for epigenetic analysis |
| US11795510B2 (en) | 2016-10-06 | 2023-10-24 | The Johns Hopkins University | Identification of epigenomic reprogramming in cancer and uses thereof |
| GB201703406D0 (en) * | 2017-03-02 | 2017-04-19 | Ucl Business Plc | Diagnostic and prognostic methods |
| CN108796079B (zh) * | 2018-06-06 | 2021-07-27 | 天津医科大学肿瘤医院 | 一种逆转录转座基因l1-fggy及其作为肺鳞癌标志物的用途 |
| US12100517B2 (en) * | 2018-10-29 | 2024-09-24 | Flatiron Health, Inc. | Generalized biomarker model |
| GB201819452D0 (en) * | 2018-11-29 | 2019-01-16 | Ucl Business Plc | Differential methylation |
| GB201819453D0 (en) | 2018-11-29 | 2019-01-16 | Ucl Business Plc | Molecular signature |
| US11396679B2 (en) | 2019-05-31 | 2022-07-26 | Universal Diagnostics, S.L. | Detection of colorectal cancer |
| US11001898B2 (en) | 2019-05-31 | 2021-05-11 | Universal Diagnostics, S.L. | Detection of colorectal cancer |
| US11898199B2 (en) | 2019-11-11 | 2024-02-13 | Universal Diagnostics, S.A. | Detection of colorectal cancer and/or advanced adenomas |
| US12467096B2 (en) | 2020-05-15 | 2025-11-11 | Universal Diagnostics, S.A. | Methods and systems for identifying methylation biomarkers |
| EP4150121A1 (en) | 2020-06-30 | 2023-03-22 | Universal Diagnostics, S.A. | Systems and methods for detection of multiple cancer types |
| JP7824952B2 (ja) * | 2020-12-04 | 2026-03-05 | エボニック オペレーションズ ゲーエムベーハー | トリ種における腸炎症状態を分類する方法 |
| JP7709178B2 (ja) * | 2021-12-09 | 2025-07-16 | 国立大学法人北海道大学 | リンパ腫に罹患したイヌの化学療法後の予後予測方法 |
| JP2023174077A (ja) * | 2022-05-27 | 2023-12-07 | 株式会社日立製作所 | Ｄｎａのメチル化レベルの測定方法、疾患予測システム、及び検査システム |
| US12606872B2 (en) | 2022-11-16 | 2026-04-21 | Universal Diagnostics, S.A. | Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using DNA methylation markers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| WO2002018631A2 (de) | 2000-09-01 | 2002-03-07 | Epigenomics Ag | Diagnose von bestehenden erkrankungen oder der prädisposition für bestimmte erkrankungen |
| JP2004524030A (ja) * | 2001-02-23 | 2004-08-12 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | 膵臓がんにおけるメチル化の異なる配列 |
| WO2003064682A1 (en) | 2001-10-18 | 2003-08-07 | Lovelace Respiratory Research Institute | Cancer monitoring by aberrant promotor methylation of the transcription factor genes pax5 alpha pax5 beta, novel loop helix loop protein, novel gene 2, and beta3 genes |
| CA2549852A1 (en) | 2003-12-11 | 2005-06-30 | Epigenomics Ag | Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
| WO2009021141A1 (en) | 2007-08-07 | 2009-02-12 | The Johns Hopkins University | Comprehensive high throughput arrays for relative methylation |
| US8399193B2 (en) * | 2007-08-30 | 2013-03-19 | City Of Hope | DNA methylation biomarkers for lung cancer |
| CN101970692B (zh) * | 2008-03-14 | 2017-02-01 | 基因特力株式会社 | 使用肺癌特异性甲基化标记基因检测肺癌的方法 |
| WO2010062914A1 (en) * | 2008-11-26 | 2010-06-03 | The Johns Hopkins University | Methods for identifying cancer risk |
-
2012
- 2012-05-10 US US14/115,617 patent/US10752953B2/en active Active
- 2012-05-10 JP JP2014510472A patent/JP2014519319A/ja not_active Withdrawn
- 2012-05-10 AU AU2012253414A patent/AU2012253414B2/en active Active
- 2012-05-10 EP EP12781728.6A patent/EP2707506B1/en active Active
- 2012-05-10 WO PCT/US2012/037362 patent/WO2012154979A2/en not_active Ceased
-
2019
- 2019-09-13 JP JP2019166951A patent/JP6954964B2/ja active Active
-
2020
- 2020-08-24 US US17/001,144 patent/US12454725B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519319A5 (https=) | ||
| CN110168099B (zh) | 用于疾病和病症分析的无细胞dna甲基化模式 | |
| KR102930572B1 (ko) | 메틸롬 분석을 이용한 암 검출 및 분류 | |
| JP7228896B2 (ja) | 乳がん患者の予後の予測方法 | |
| Hrašovec et al. | TMEM25 is a candidate biomarker methylated and down‐regulated in colorectal cancer | |
| US20140113978A1 (en) | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof | |
| WO2014062218A1 (en) | Colorectal cancer dna methylation markers | |
| FI2831279T3 (fi) | Nopea aneuploidian havaitseminen | |
| JP2021531016A (ja) | 無細胞ｄｎａ損傷分析およびその臨床応用 | |
| EP2982986B1 (en) | Method for manufacturing gastric cancer prognosis prediction model | |
| JP2020527958A (ja) | 無細胞ウイルス核酸を用いる癌スクリーニングの強化 | |
| KR20240104202A (ko) | 순환 종양 핵산 분자의 다중모드 분석 | |
| WO2016168174A1 (en) | Predicting the occurrence of metastatic cancer using epigenomic biomarkers and non-invasive methodologies | |
| CA3182993A1 (en) | Detection and classification of human papillomavirus associated cancers | |
| EP4630585A2 (en) | Systems and methods for cell-free nucleic acids methylation assessment | |
| JP2012513752A (ja) | 結腸直腸癌細胞を含む試料を型判別するための方法および手段 | |
| Xue et al. | Evaluation and integration of cell-free DNA signatures for detection of lung cancer | |
| WO2023152568A2 (en) | Compositions and methods for characterizing lung cancer | |
| García-Giménez et al. | Epigenetic biomarkers for disease diagnosis | |
| JP2024519082A (ja) | 肝細胞がんのｄｎａメチル化バイオマーカー | |
| JP2014128260A (ja) | 甲状腺腫瘍の性状の判別を補助する方法およびその方法に用いるマーカーセット | |
| RU2683251C1 (ru) | Способ диагностики светлоклеточного почечно-клеточного рака и способ прогнозирования метастазирования на основе группы генов микроРНК | |
| WO2023168345A2 (en) | Methylated dna markers and assays thereof for use in detecting colorectal cancer | |
| WO2023159817A1 (zh) | 一种基因诊断探针及其应用 | |
| Kristiansen et al. | Methylated DNA for monitoring tumor growth and regression: how do we get there? |